Risk factors, antithrombotic treatment and outcome in retinal vein occlusion: An age-related prospective cohort study

European Journal of Haematology

Volumn 90, Issue 5, 2013, Pages 426-433

  Sartori, Maria Teresa ^a   Barbar, Sofia ^a   Donà, Annalisa ^a   Piermarocchi, Stefano ^a   Pilotto, Elisabetta ^a   Saggiorato, Graziella ^a   Prandoni, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anticoagulant treatment; Antiplatelet agents; Cardiovascular risk factors; Retinal vein occlusion; Thrombophilia

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 5 LEIDEN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PROTEIN C; WARFARIN;

ACUTE CORONARY SYNDROME; ADULT; AGE; AGED; ANTERIOR ISCHEMIC OPTIC NEUROPATHY; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD VISCOSITY; BRANCH RETINAL VEIN OCCLUSION; CARDIOVASCULAR RISK; CENTRAL RETINA VEIN OCCLUSION; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; RECANALIZATION; RETINA VEIN OCCLUSION; RISK FACTOR; THROMBOPHILIA; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ADULT; AGED; BLOOD COAGULATION DISORDERS; CARDIOVASCULAR DISEASES; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; RISK FACTORS;

EID: 84876741798     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12099     Document Type: Article

References (42)

1. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY, International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313-9.
2. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000;98:133-41.
3. Cheung N, Klein R, Wang JJ, Cotch MF, Islam AF, Klein BE, Cushman M, Wong TY. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multi-ethic study of atherosclerosis. Invest Ophthalmol Vis Sci 2008;49:4297-302.
4. Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 2006;124:726-32.
5. Klein BA, Olwin JH. A survey of the pathogenesis of retinal vein occlusion. Arch Ophthalmol 1956;56:207-47.
6. Battaglia Parodi M, Bandello F. Branch retinal vein occlusion: classification and treatment. Ophtalmologica 2009;223:298-305.
7. Yau JWY, Lee P, Wong TY, Best J, Jenkins A. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J 2008;38:904-10.
8. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001;131:61-77.
9. Di Capua M, Coppola A, Albisinni R, Tufano A, Guida A, Di Minno MND, Cirillo F, Loffredo M, Cerbone AM. Cardiovascular risk factors and outcome in patients with retinal vein occlusion. J Thromb Thrombolysis 2009;30:16-22.
10. O'Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol 2008;126:692-9.
11. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996;114:545-54.
12. The Eye Disease Case-Control Study Group. Risk factors for branch retinal vein occlusion. Am J Ophthalmol 1993;116:286-96.
13. Weger M, Renner W, Steinbrugger I, Cichocki L, Temmel W, Stanger O, El-Shabrawi Y, Lechner H, Schmut O, Haas A. Role of thrombophilic gene polymorphisms in branch retinal vein occlusion. Ophtalmology 2005;112:1910-5.
14. Arsene S, Delahousse B, Regina S, Le Lez ML, Pisella PJ, Gruel Y. Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age. Thromb Haemost 2005;94:101-6.
15. Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005;93:1021-6.
16. Rehak M, Rehak J, Müller M, et al. The prevalence of activated protein C resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis. Thromb Haemost 2008;99:925-9.
17. Marcucci R, Bertini L, Giusti B, Brunelli T, Fedi S, Cellai AP, Poli D, Pepe G, Abbate R, Prisco D. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001;86:772-6.
18. Rehak M, Müller M, Scholz M, Wiercinska J, Niederwieser D, Wiedemann P. Antiphospholipid syndrome and retinal vein occlusion: meta-analysis of published studies. Ophthalmologe 2009;106:427-34.
19. Rubinstein K, Jones EB. Retinal vein occlusion: long-term prospects: 10 years' follow-up of 143 patients. Br J Ophthalmol 1976;60:148-50.
20. Cugati S, Wang JJ, Knudtson MD, Rochtchina E, Klein R, Klein BE, Wong TY, Mitchell P. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology 2007;114:520-4.
21. Tsaulomas MD, Kirwan J, Vinall H, O'Leary MB, Prior P, Kritzinger EE, Dodson PM. Nine year follow-up study of morbidity and mortality in retinal vein occlusion. Eye 2000;14:821-7.
22. Elman MJ, Bhatt AK, Quinlan PM, Enger C. The risk for systemic vascular diseases and mortality in patients with central retinal vein occlusion. Ophthalmology 1990;97:1543-8.
23. Mansour AM, Walsh JB, Henkind P. Mortality and morbidity in patients with central retinal vein occlusion. Ophthalmologica 1992;204:199-203.
24. Ho JD, Liou SW, Lin HC. Retinal vein occlusion and the risk of stroke development: a five-year follow-up study. Am J Ophthalmol 2009;147:283-90.
25. Glacet-Bernard A, Zourdani A, Milhoub M, Maraqua N, Coscas G, Soubrane G. Effect of isovolemic hemodilution in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2001;239:909-14.
26. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol 1994;118:421-9.
27. Houtsmuller AJ, Vermeulen JA, Klompe M, Zahn KJ, Henkes HE, Baarsma GS, Tijssen J. The influence of ticlopidine on the natural course of retinal vein occlusion. Agents Actions Suppl 1984;15:219-29.
28. Ageno W, Cattaneo R, Manfredi E, et al. Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study. Thromb Res 2010;125:137-41.
29. Farahvash MS, Moghaddam MM, Moghimi S, Mohammadzadeh S. Dalteparin in the management of recent onset central retinal vein occlusion: a comparison with acetylsalicylic acid. Can J Ophthalmol 2008;43:79-83.
30. Pinna A, Simula P, Zinellu A. Subcutaneous nadroparin calcium in the treatment of recent onset retinal vein occlusion: a pilot study. J Ocul Pharmacol Ther 2012;28:448-54.
31. Lazo-Langner A, Hawel J, Ageno W, Kovacs MJ. Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials. Haematologica 2010;95:1587-93.
32. Squizzato A, Manfredi E, Bozzato S, Dentali F, Ageno W. Antithrombotic and fibrinolytic drugs for retinal vein occlusion: a systematic review and a call for action. Thromb Haemost 2010;103:271-6.
33. Hattenbach LO, Friedrich Arndt C, Lerche R, Scharrer I, Baatz H, Margaron F, Richard G, Behrens-Baumann W, Ohrloff C. Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion. Retina 2009;29:932-40.
34. Simioni P, Sanson BJ, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999;81:198-202.
35. Rehak J. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 2008;33:111-31.
36. Marcucci R, Sofi F, Grifoni E, Sodi A, Prisco D. Retinal vein occlusions: a review for the internist. Intern Emerg Med 2011;6:307-14.
37. Kuhli-Hattenbach C, Scharrer I, Lüchtenberg M, Hattenbach LO. Coagulation disorders and the risk of retinal vein occlusion. A subgroup analysis. Thromb Haemost 2010;103:299-305.
38. Lattanzio R, Sampietro F, Ramoni A, Fattorini A, Brancato R, D'Angelo A. Moderate hyperhomocysteinemia and early-onset central retinal vein occlusion. Retina 2006;26:65-70.
39. Farahvash MS, Moradimogadam M, Farahvash MM, Mohammadzadeh S, Mirshahi A. Dalteparin versus aspirin in recent-onset branch retinal vein occlusion: a randomized clinical trial. Arch Iran Med 2008;11:418-22.
40. Leoncini G, Bruzzese D, Signorello MG, Armani U, Piana A, Ghiglione D, Camicione P. Platelet activation by collagen is increased in retinal vein occlusion. Thromb Haemost 2007;97:218-27.
41. Leoncini G, Signorello MG, Segantin A, Giacobbe E, Armani U, Piana A, Camicione P. In retinal vein occlusion platelet response to thrombin is increased. Thromb Res 2009;124:48-55.
42. Christoffersen N, Gade E, Knudsen L, Juel K, Larsen M. Mortality in patients with branch retinal vein occlusion. Ophthalmology 2007;114:1186-9.